A. Tumor volume (expressed as the mean ± SEM) of U87-beared mice in treatment of KU0060648 (10 or 50 mg/kg, once daily, i.p.) and TMZ (10 mg/kg, thrice a week, i.p.) alone, or co-administrated KU0060648 (10 or 50 mg/kg, once daily, i.p.) and TMZ (10 mg/kg, thrice a week, i.p.). Tumor size was measured every three days for the indicated period starting at day 14. The observation period was 30 days. Control mice were received the 0.9% saline. n=5 per group. B. Kaplan-Meier curves for illustration of the survival periods of xenograft-bearing mice in the treatment. n=5 per group C. IHC staining of subcutaneous xenografts samples from each treatment group. Representative IHC staining of p-DNA-PKcs (S2056), p-AKT (S473), Ki-67, c-Myc, MMP-9, VEGF, Survivin, cleaved caspase-3 and γH2AX in serial sections (magnification, ×10).